Consolidation, maintenance and continuous therapy for multiple myeloma in the era of novel agents / 肿瘤研究与临床

With the application of novel agents and high-dose chemotherapy with autologous stem cell transplantation(ASCT),the survival time of multiple myeloma(MM) has been significantly prolonged.However,due to the biological characteristics of myeloma and minimal residual disease after initial treatment,the disease courses of most MM patients show a series of remissions and relapses.Hence,it is necessary to apply consolidation and maintenance therapy after ASCT and continuous therapy for transplant-ineligible patients.This paper reviews the advances in consolidation,maintenance and continuous therapy for MM in the era of novel agents.

Research progress of regulatory T cells in multiple myeloma / 白血病·淋巴瘤

Regulatory T (Treg) cells are a group of cells with immunosuppressive function which play important roles in tumor immunity.This paper reviews the advances of Treg cells in multiple myeloma (MM),including the basic characteristics of Treg cells,interaction of Treg cells and myeloma cells,influences of antimyelona treatnent on Treg cells.

Advances in elderly patients with newly diagnosed multiple myeloma from the 19th European Hematology Association Annual Congress / 白血病·淋巴瘤

As the introduction of novel agents,the median overall survival of elderly newly diagnosed multiple myeloma patients has increased roughly from 30 to 60 months.But patients with high risk prognostic features still have a poor clinical outcome.This paper which combined the 19th annual congress of the European Hematology Association (EHA) reviews the advances in elderly patients with newly diagnosed multiple myeloma,including standard of care,the way to treatment and prognostic factors.